Atai Life Sciences Balance Sheet Health
Financial Health criteria checks 4/6
Atai Life Sciences has a total shareholder equity of $146.3M and total debt of $25.1M, which brings its debt-to-equity ratio to 17.2%. Its total assets and total liabilities are $197.5M and $51.2M respectively.
Key information
17.2%
Debt to equity ratio
US$25.14m
Debt
| Interest coverage ratio | n/a |
| Cash | US$85.92m |
| Equity | US$146.32m |
| Total liabilities | US$51.20m |
| Total assets | US$197.52m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 9VC's short term assets ($114.1M) exceed its short term liabilities ($19.6M).
Long Term Liabilities: 9VC's short term assets ($114.1M) exceed its long term liabilities ($31.6M).
Debt to Equity History and Analysis
Debt Level: 9VC has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 9VC's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9VC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 9VC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 26% each year